Check Point Software Technologies Ltd. (NASDAQ:CHKP) shareholders are probably feeling a little disappointed, since its shares fell 4.9% to US$120 in the week after its latest quarterly results. Check Point Software Technologies reported US$509m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$1.42 beat expectations, being 5.5% higher than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
View our latest analysis for Check Point Software Technologies
Taking into account the latest results, the current consensus from Check Point Software Technologies’ 28 analysts is for revenues of US$2.12b in 2021, which would reflect
Intel shares tumbled on Friday after the chip giant posted a drop in revenue for its data center processor business.
Some analysts warn that Intel, the biggest semiconductor maker in the world, faces rougher waters in the coming year, amid stiffer challenges from rivals AMD and Nvidia.
“Fundamentals are now deteriorating at an alarming pace,” Bernstein analyst Stacy Rasgon told clients in a note. “We have to believe that 2021 is going to be worse.”
Other analysts offered a more upbeat view: “Intel still has a tremendous amount of intellectual property that can be deployed to make money well into the future,” analyst Roger Kay told Business Insider, calling it “a solid company underneath.”
Visit Business Insider’s homepage for more stories.
Intel is having a really terrible year, and some analysts predict the next will even be worse.
The chip giant’s shares plunged more than 11% on Friday after reporting
GoodRx (GDRX) – Get Report shares fell Monday after the online-prescription-shopping platform received four buy ratings and four holds from analysts who initiated ratings on the company.
The bullish analysts see a huge potential customer base for GoodRx, which went public last month. The neutral analysts express concern about valuation, given GoodRx’s 55% surge from its $33 initial-public-offering price.
The Santa Monica, Calif., company’s shares recently traded at $50.55, down 4.7%.
Morgan Stanley analyst Ricky Goldwasser rates GoodRx overweight with a $57 share-price target.
“GoodRx is the largest healthcare-focused Internet platform that provides users access to prescription drug discounts nationwide,” she wrote in a commentary.
“Leveraging its Internet platform and relationships with health-care stakeholders, GoodRx has unbundled traditional pricing mechanism to create a more equitable cash prescription marketplace for consumers filling generic scripts.”
Goldwasser added, “The company is in early phases of expanding into subscription prescription offering, telehealth
Oct. 19 (UPI) — Ransomware gangs, some capable of hijacking major computer systems in less than an hour, have emerged as the most common cybersecurity threat this year, according to a new report.
Cybercriminals have become so efficient at staging ransomware attacks that some skilled gangs need only 45 minutes between initial entry to a system and locking it down for ransom, Microsoft analysts said in their annual Digital Defense Report.
“This report makes it clear that threat actors have rapidly increased in sophistication over the past year, using techniques that make them harder to spot and that threaten even the savviest targets,” Microsoft said.
“In addition to attacks becoming more sophisticated, threat actors are showing clear preferences for certain techniques, with notable shifts towards credential harvesting and ransomware, as well as an increasing focus on Internet of Things devices.”
The rising sophistication of ransomware attacks has come in tandem
With earnings season gathering pace, now is the time to re-evaluate your portfolio. However, in such an unpredictable environment, investors need to be particularly savvy when making critical investing decisions.
“Markets are now hoping for (and trading on) a smooth election, a big stimulus, the end of the pandemic, and the economy being back to 2019 normal early next year,” said Brad McMillan, chief investment officer at Commonwealth Financial Network. This makes the market particularly vulnerable to disappointment. Indeed, the S&P 500 pulled back this week as stimulus hopes wane and corona fears resurface.
In order to find compelling investing opportunities, it’s worth following the latest stock recommendations from analysts with a proven track record of success. TipRanks analyst forecasting service attempts to pinpoint Wall Street’s best-performing analysts. These are the analysts with the highest success
LONDON – Regulators in China could be a major barrier in Nvidia’s attempt to buy U.K. chipmaker Arm from SoftBank for $40 billion, according to analysts.
The mega-deal, which would create the largest chip company in the West by market value and global reach, was announced at the start of September. But it is far from being home and dry, with multiple regulators able to weigh in including China’s Ministry of Commerce (MOFCOM) and China’s State